EGFR and non-small cell lung carcinoma: However, the secondary mutations in the EGFR gene (T790M) and activation of bypass pathways (such as AXL) leads to the most eventually acquired resistance among NSCLC patients that initially respond to EGFR-TKIs (Chong & Jänne, 2013; Gridelli et al., 2015).